Cash generated from the ‘faster to market’ personal care products will assist in funding pharmaceutical opportunities to a stage where a rewarding partnership/license agreement can be negotiated.
“Our personal care division is consistently growing, providing multiple opportunities for Phosphagenics which are low-risk.” As such “I can say that we are truly a low-risk company.”
The strength of Phosphagenics business “is the versatility of our technology, acting as a competitive advantage for us,” as the company operates alongside 42 other of pharmaceutical companies. “Essentially it can be delivered in a gel, patch or spray form.”
What does she mean by the above and why was this not elaborted upon in a newsletter. This is what investors need to know. PoS.
parathyroid hormone., page-7
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $205 | 72.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 90468113 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 61728026 | 18 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |